Rank
Identify disease mechanisms across omics data, targets, and safe-drug libraries.
Agemica's mission is to increase the Healthy Human Life Span to 150 Years
Our approach
A new standard in AI discovery.
Agemica ranks disease mechanisms, tests predicted combinations in human ex-vivo systems, measures cell death and safety, then advances only the strongest candidates.
Test
Evaluate ranked combinations in ex-vivo human cancer models.
Kill
Measure cancer-cell death, tumor-volume reduction, and healthy-cell safety.
Advance
Advance the strongest ex-vivo candidates toward humanized-mouse studies, IND-enabling work, and future clinical development.
Team
Leadership
Prof. Ronjon Nag
AI founder and Stanford genetics adjunct professor.
Cambridge PhDMIT MS
Dr. Yasaman Kalantar-Motamedi
Computational biologist focused on AI drug discovery and multi-omics.
Cambridge PhDUCL research
Prof. Michael Snyder
Stanford genomics leader in multi-omics and precision medicine.
Stanford GeneticsMulti-omics
Prof. Jayakumar Rajadas
Drug delivery and regenerative biomaterials expert.
Stanford ADDReB LabDrug delivery
Anastasiya Giarletta
Principal, R42 Group — AI, longevity, and founder ecosystem.
R42 GroupPortfolio
